Malignant fibrous neoplasms of long bones: analysis of the surveillance, epidemiology, and end results database from 1973 to 2015.
Fibromyxosarcoma
Fibrosarcoma
Long bones
Malignant fibrous histiocytoma
Malignant fibrous neoplasms (MFN)
Periosteal fibrosarcoma
Prognosis
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
22 Jan 2020
22 Jan 2020
Historique:
received:
17
12
2018
accepted:
26
11
2019
entrez:
24
1
2020
pubmed:
24
1
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Malignant fibrous neoplasms (MFN) of long bones are rare lesions. Moreover, the prognostic determinants of MFN of long bones have not been reported. This study aimed to present epidemiological data and analyse the prognostic factors for survival in patients with MFN. The Surveillance, Epidemiology, and End Results (SEER) programme database was used to screen patients with malignant fibrous neoplasms (MFN) of long bones from 1973 to 2015, with attention to fibrosarcoma, fibromyxosarcoma, periosteal fibrosarcoma and malignant fibrous histiocytoma. The prognostic values of overall survival (OS) and cancer-specific survival (CSS) were assessed using the Cox proportional hazards regression model with univariate and multivariate analyses. The Kaplan-Meier method was used to obtain OS and CSS curves. A total of 237 cases were selected from the SEER database. Malignant fibrous histiocytoma was the most common form of lesion in long bones. Multivariate analysis revealed that independent predictors of OS included age, stage, tumour size and surgery. Age, stage, tumour size and surgery were also independent predictors of CSS. Additionally, the most significant prognostic factor was whether metastasis had occurred at the time of initial diagnosis. Among patients with MFN of long bones, age (> 60 years), tumour size (> 10 cm), distant stage, and non-surgical treatment are factors for poor survival.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant fibrous neoplasms (MFN) of long bones are rare lesions. Moreover, the prognostic determinants of MFN of long bones have not been reported. This study aimed to present epidemiological data and analyse the prognostic factors for survival in patients with MFN.
MATERIALS AND METHODS
METHODS
The Surveillance, Epidemiology, and End Results (SEER) programme database was used to screen patients with malignant fibrous neoplasms (MFN) of long bones from 1973 to 2015, with attention to fibrosarcoma, fibromyxosarcoma, periosteal fibrosarcoma and malignant fibrous histiocytoma. The prognostic values of overall survival (OS) and cancer-specific survival (CSS) were assessed using the Cox proportional hazards regression model with univariate and multivariate analyses. The Kaplan-Meier method was used to obtain OS and CSS curves.
RESULTS
RESULTS
A total of 237 cases were selected from the SEER database. Malignant fibrous histiocytoma was the most common form of lesion in long bones. Multivariate analysis revealed that independent predictors of OS included age, stage, tumour size and surgery. Age, stage, tumour size and surgery were also independent predictors of CSS. Additionally, the most significant prognostic factor was whether metastasis had occurred at the time of initial diagnosis.
CONCLUSION
CONCLUSIONS
Among patients with MFN of long bones, age (> 60 years), tumour size (> 10 cm), distant stage, and non-surgical treatment are factors for poor survival.
Identifiants
pubmed: 31969161
doi: 10.1186/s12891-019-2971-8
pii: 10.1186/s12891-019-2971-8
pmc: PMC6977304
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
48Subventions
Organisme : Natural Science Foundation of Zhejiang Province (CN)
ID : LQ18H060001
Organisme : Natural Science Foundation of Zhejiang Province (CN)
ID : LY17H060004
Organisme : Zhejiang Province Medical and Health project
ID : 2018269731
Organisme : Zhejiang Province Chinese Medicine Project
ID : 2015ZB028
Organisme : National Natural Science Foundation of China (CN)
ID : 81602312
Références
Spine J. 2017 May;17(5):645-655
pubmed: 27856382
Cancer Manag Res. 2018 Oct 09;10:4381-4391
pubmed: 30349371
Laryngoscope. 2018 Apr;128(4):885-888
pubmed: 28988458
Spine (Phila Pa 1976). 2017 May 1;42(9):644-652
pubmed: 28441682
Cancer. 1963 Mar;16:331-44
pubmed: 13940913
J Surg Res. 2011 Jun 15;168(2):e173-80
pubmed: 21470630
Int Forum Allergy Rhinol. 2016 Feb;6(2):201-5
pubmed: 26370489
Cancer Genet Cytogenet. 2000 Apr 15;118(2):89-98
pubmed: 10748288
Cancer. 1992 Sep 1;70(5):1089-101
pubmed: 1515984
Cancer. 2014 Jun 15;120(12):1763-74
pubmed: 24648013
Dermatol Pract Concept. 2017 Jul 31;7(3):44-46
pubmed: 29085719
Cancer Invest. 2013 Feb;31(2):83-91
pubmed: 23320812
Cancer Manag Res. 2018 May 14;10:1191-1199
pubmed: 29795990
J Craniofac Surg. 2017 Jan;28(1):182-184
pubmed: 27922973
Am J Clin Oncol. 2002 Feb;25(1):16-22
pubmed: 11823689
Cancer Manag Res. 2018 Oct 10;10:4401-4410
pubmed: 30349373
Cancer Manag Res. 2018 Oct 03;10:4181-4189
pubmed: 30323674
Scand J Urol. 2014 Oct;48(5):420-5
pubmed: 24730474
J Surg Oncol. 2017 Aug;116(2):252-257
pubmed: 28420036
Am J Clin Oncol. 2014 Oct;37(5):430-2
pubmed: 23388563
J Surg Res. 2012 Jan;172(1):123-30
pubmed: 20869082
Eklem Hastalik Cerrahisi. 2016 Aug;27(2):94-9
pubmed: 27499321
Cancer Manag Res. 2018 Oct 11;10:4479-4489
pubmed: 30349380
J Orthop Surg Res. 2018 Apr 6;13(1):76
pubmed: 29625617
Cancer. 1961 May-Jun;14:469-82
pubmed: 13751857
Cancer. 1976 Jun;37(6):2912-28
pubmed: 949712